Table 1 Baseline characteristics of T-cell lymphoma patients
From: Quantitative evaluation of interim positron emission tomography in peripheral T-cell lymphoma
ALK-neg. peripheral T-cell lymphomas | ALK-pos. anaplastic large cell lymphoma | |||
|---|---|---|---|---|
Included | Excluded | Included | Excluded | |
No. of patients | 43 | 12 | 14 | 7 |
Peripheral T-cell lymphoma, not otherwise specified | 15 | 5 | n.a | n.a |
Angioimmunoblastic T-cell lymphoma | 13 | 5 | n.a | n.a |
ALK-negative anaplastic large cell lymphoma | 12 | 1 | n.a | n.a |
Unclassified T-cell lymphoma | 3 | 1 | n.a | n.a |
Age – median (range), years | 61 (26–77) | 70 (29–79) | 34 (20–66) | 32 (19–54) |
Male sex | 30 (70%) | 9 (75%) | 9 (64%) | 7 (100%) |
ECOG performance status ≥ 2 | 3 (7%) | 1 (8%) | 0 (0%) | 1 (14%) |
Ann Arbor stage III or IV | 30 (70%) | 8 (67%) | 5 (36%) | 5 (71%) |
Extranodal sites > 1 | 10 (23%) | 1 (8%) | 2 (14%) | 0 (0%) |
Lactate dehydrogenase > ULN | 25 (58%) | 7 (58%) | 3 (21%) | 1 (14%) |
International Prognostic Index | ||||
Low risk | 16 (37%) | 2 (17%) | 11 (79%) | 5 (71%) |
Low-intermediate risk | 9 (21%) | 6 (50%) | 3 (21%) | 2 (29%) |
High-intermediate risk | 12 (28%) | 3 (25%) | 0 (0%) | 0 (0%) |
High risk | 6 (14%) | 1 (8%) | 0 (0%) | 0 (0%) |